Market Overview - Investor focus is shifting beyond mega-cap stocks, with earnings revisions improving across various sectors, including small caps, which may unlock value dislocations accumulated over the last three years [1] - For small-cap outperformance to continue, consistent upward earnings revisions and a compression of the valuation spread between small and large caps are necessary [1] Portfolio Positioning - Interest is growing in mid-caps, small-caps, international stocks, and investment-grade fixed income, moving away from a primary focus on US mega-caps [2] - Concerns exist regarding market concentration in mega-cap tech companies and potential disappointments in that sector [2] - The next phase of AI-related trades may involve small and mid-cap companies leveraging AI products for productivity gains, as these firms are more labor-intensive and may have greater earnings leverage if AI enhances productivity [2] Citius Oncology Inc. (NASDAQ:CTOR) - Citius Oncology has entered an exclusive distribution agreement with Uniphar to expand its oncology treatment, LYMPHIR, in Europe, marking its third major international agreement [7] - LYMPHIR is currently FDA-approved in the US but lacks commercial marketing authorization in Europe, limiting its availability to specific patient groups under local legal frameworks [8] - The drug targets patients with Stage I-III cutaneous T-cell lymphoma, functioning as a recombinant fusion protein to selectively destroy cancerous T-cells [9][10] Ceragon Networks Ltd. (NASDAQ:CRNT) - Ceragon Networks reported Q4 2025 revenue of $82.3 million, a 23% decline from Q4 2024, with full-year revenue totaling $338.7 million, down 14.1% year-over-year [11] - Management is optimistic for 2026, projecting revenue guidance of $355 to $385 million, driven by the launch of new products and a multimillion-dollar private network contract in the Asia-Pacific region [12] - The company is diversifying revenue streams through private networks in mining and energy sectors while managing supply chain costs by qualifying secondary sources [13][14]